ZUG, Switzerland, Jan. 5, 2021 /PRNewswire/ -- Pharvaris, a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback